# Araris Biotech (Taiho)

Source: https://onco.cc/companies/araris/  
OnCo record `araris` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Swiss linker-technology company (AraLinQ) acquired by Taiho for up to $1.14B; first clinical ADC ARC-02 (CD79b) dosed in June 2026.

## Summary

Araris Biotech, based in Zurich, is the Swiss linker-technology company behind AraLinQ, acquired by Taiho for up to 1.14 billion dollars, and its first clinical ADC, ARC-02, was dosed in June 2026. Taiho paid 400 million dollars at closing in 2025 with up to 740 million dollars in milestones, and ARC-02, a CD79b-targeted MMAE ADC built with AraLinQ site-specific conjugation, entered phase 1 in non-Hodgkin lymphoma in June 2026 as the first AraLinQ product in humans. OnCo links it to diffuse large B-cell lymphoma, to ADCs and site-specific conjugation and linker chemistry, to Taiho, and to the idea of platform designation for ADC linker-payloads so manufacturing data carry across. Whether a cleaner linker changes clinical outcomes, or only manufacturing, is the question ARC-02 will start to answer. Taiho has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Zurich
- Type: biotech
- Website: https://www.ararisbiotech.com

## Sources

- ARC-02 phase 1: https://www.taiho.co.jp/en/release/2026/20260428.html

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Site-specific conjugation & linker chemistry](https://onco.cc/technologies/site-specific-conjugation/)
- trials: [A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)](https://onco.cc/trials/nct04256317/), [A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.](https://onco.cc/trials/nct05967689/), [Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07710885/), [Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas](https://onco.cc/trials/nct02503423/), [Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors](https://onco.cc/trials/nct05945823/), [Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement](https://onco.cc/trials/nct05727176/), [Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities](https://onco.cc/trials/nct04683250/)
- companies: [Taiho Pharmaceutical (Otsuka)](https://onco.cc/companies/taiho/)
- ideas: [Platform designation for ADC linker-payloads so manufacturing data carry across](https://onco.cc/ideas/idea-reg-adc-platform-designation/)
- roadmaps: [Drug discovery roadmap: screening in mice → maps of dependency → designing in silico](https://onco.cc/roadmaps/drug-discovery-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/araris.json